Peter Barrett is a Partner in the life sciences group and joined Atlas Venture in 2002.
Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics. Within two years of the founding of the company (1998), Celera announced the first successful sequencing of the human genome. Peter helped launch Celera as a publicly traded entity in 1999. He led Celera's strategic alliances and acquisitions and participated in raising nearly $1 billion in capital for the company.
Prior to Celera, Peter held senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development. During his tenure, he expanded the life science business units through a series of licensing agreements, partnerships and acquisitions including: Applied Biosystems and PerSeptive Biosystems. Also during this time, Peter co-founded Celera Genomics with Dr. J. Craig Venter and the Applera Corporation management team.
Peter currently serves on the boards of Atlas Venture portfolio companies Archemix, Aureon Laboratories, Helicos Biosciences (NASDAQ: HLCS), InfaCare Pharmaceuticals, IVREA Pharmaceuticals, Stromedix, Vitae Pharmaceuticals and Zafgen. He is chairman of the board at IVREA and Zafgen and lead Director at Archemix. Previous Board seats include Atlas Venture portfolio companies Alnylam (NASDAQ: ALNY) and Momenta Pharmaceuticals (NASDAQ: MNTA).
Peter is currently Vice Chairman of the Advisory Council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University, as well as Adjunct Professor at the Barnett Institute. He also serves as President of the Autism Consortium, a non-profit institution.
Peter received his Bachelor of Science in Chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Ph.D. in Analytical Chemistry from Northeastern University. He also completed Harvard Business School's Management Development Program.
Flotte has received numerous honors and awards including the Society for Pediatric Research's E. Mead Johnson Award for Outstanding Scientific Contributions and the University of Florida Faculty Research Prize in Clinical Science. He is a member of the American Society for Gene Therapy and the American Society of Microbiology, among many other professional associations.
